Press releases
You will be able to find all of our recent press releases. You can search by keyword or filter by year/business category to quickly find what you need.
You may also want to view our USA press releases and Asia press releases.
Press releases for our local operating companies can be viewed on our individual country websites.
Filter by
-
GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare
Brian join GSK’s Corporate Executive Team and will continue as a member of the Board of the Consu...
Read more -
GlaxoSmithKline completes sale of remaining Aspen shares
GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Asp...
Read more -
GlaxoSmithKline announces intention to sell remaining holding in Aspen
GSK intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd ("Aspen").
Read more -
GSK announces US regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland...
Read more -
GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease
It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.
Read more -
Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline
Emma Walmsley, currently CEO of GSK’s Consumer Healthcare division, is appointed GSK CEO Designat...
Read more -
GSK sets out further steps to address emerging global health security challenges
GSK will set out a series of steps to further address emerging global health challenges
Read more -
GSK’s candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
GSK on track to file regulatory applications in 2016
Read more -
GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland...
Read more -
GSK divests non-core assets to Aspen
A series of agreements Between Aspen and GSK through focusing on core therapeutic areas
Read more -
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress
Improvements in lung function and health-related quality of life supported by statistically signi...
Read more -
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Cases of meningitis B halved after ten months
Read more -
GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
The results from the pioneering Salford Lung Study (SLS) have been published in the New England J...
Read more -
NEJM publishes results of GSK’s long-term LABA safety study of Advair® Diskus® in children aged 4-11 years with asthma
Headline results reported in March, demonstrated that the study had achieved its primary endpoint.
Read more -
GSK’s continued commitment to innovative respiratory research demonstrated in European Respiratory Society congress data presentations
More than 30 abstracts from the company will be featured at the meeting.
Read more -
ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence...
Read more -
GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines
GSK will hold a 55% equity interest in the new jointly owned company and Verily will hold 45%.
Read more -
Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016
GSK delivers further progress against strategy with strong Q2 performance
Read more -
GSK in-licenses anti-IL-33R monoclonal antibody for severe asthma from Janssen
Agreement further strengthens respiratory pipeline of targeted biological therapies
Read more -
GSK announces significant new investment in UK manufacturing network
GSK today announced £275 million of new investments at three of its manufacturing sites in the UK...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
-
Investors
Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting
